HTL Biotechnology opens €15M polynucleotide plant in France

Image
HTL Biotechnology opens €15M polynucleotide plant in France

JAVENÉ, France – November 13, 2026 -- HTL Biotechnology inaugurated HTL8, a €15 million production unit for pharmaceutical-grade polynucleotides, on November 12 at its Javené site in Ille-et-Vilaine. The investment equals 15% of the company's €100 million investment plan for 2022-2026, which leaves €85 million for all other projects under that plan.

HTL8 takes 15% of the 2022-2026 investment budget

The €100 million plan was launched in 2022 and runs for five years. By FairsOnline's calculation, that is an average of €20 million a year. HTL8 therefore costs less than one average year of the plan's spending.

The unit is dedicated to purifying polynucleotides, which are chains of nucleotides. HTL manufactures them from DNA extracted from wild Alaskan salmon milt, a co-product of the salmon industry. The company says HTL8 combines automation with tighter control of critical process parameters.

HTL targets regenerative medicine, ophthalmology and dermatology

The company names regenerative medicine, ophthalmology and dermatology (wound healing) as the applications HTL8 is meant to support. It says it is also responding to rising demand for polynucleotides, particularly in Asian markets, where it has subsidiaries. HTL sells its biopolymers to healthcare companies, which use them to develop treatments.

CEO François Fournier says the unit anchors industrial capability in France and lets HTL support customers closely in their markets. The company did not disclose HTL8's production capacity.

HTL employs nearly 300 people worldwide and combines production, R&D and quality activities at Javené. Outside France, its US subsidiary HTL Biotechnology Innovation Inc. (New Jersey) has acquired a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3). The group is also building a

Published by:
fairsonline_team
Industries